Bristol-Myers SquibbAssociate Director
Apr. 2019 - Aug. 2023•Developed strategies to meet the demand of the overall biomarker assay support for a large challenging and diverse portfolio. •Provided scientific and technical oversight to scientists through the development, validation and implementation of fit-for-purpose biomarker assays for the analysis of clinical samples in a GxP environment or assays contracted to CROs. •Harmonized and implemented new processes across the large molecule and small molecule groups that resulted in a 50% reduction in audit findings per study. Additionally, under my leadership, an audit of a GLP study yielded no audit findings for the first time in the department’s history and incidents requiring data recall were diminished to 1 recall out of 184 studies over a 5 year period.
•Led the Study Support and Compliance group that focused on regulated analysis, compliance risk mitigation, and risk mitigation for BMS’s most technically challenging assets and critical assay types by establishing internal expertise prior to outsourcing.
•Designed and executed a risk based compliance strategy within Bioanalytical Sciences to ensure compliance with evolving Health Authority and industry standards for data integrity, 21 CFR Part 11, and Part 58.
•Served as the bioanalytical or biomarker SME for cardiovascular, oncology, and immuno-oncology programs to ensure data for regulatory filings was accurate, precise, and reproducible.